Similar articles for PMID: 15767607

Year	Number of Results
2004	1
2005	3
2006	7
2007	10
2008	10
2009	12
2010	3
2011	8
2012	11
2013	2
2014	2
2016	3
2017	1
2018	2
2019	1
2024	0

1

A man whose scapula was spared a drug-associated rash.

Sanz A, del Valle ML. Sanz A, et al. CMAJ. 2005 Mar 15;172(6):745. doi: 10.1503/cmaj.1040795. CMAJ. 2005. PMID: 15767607 Free PMC article. No abstract available.

2

Erlotinib induced skin rash spares skin in previous radiotherapy field.

Mitra SS, Simcock R. Mitra SS, et al. J Clin Oncol. 2006 Jun 1;24(16):e28-9. doi: 10.1200/JCO.2005.05.1631. J Clin Oncol. 2006. PMID: 16735697 No abstract available.

3

Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.

Eames T, Landthaler M, Karrer S. Eames T, et al. Eur J Dermatol. 2007 Nov-Dec;17(6):552-3. doi: 10.1684/ejd.2007.0286. Epub 2007 Oct 19. Eur J Dermatol. 2007. PMID: 17951151 No abstract available.

4

Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects.

Gerber PA, Enderlein E, Homey B, Muller A, Boelke E, Budach W. Gerber PA, et al. J Clin Oncol. 2007 Oct 10;25(29):4697-8; author reply 4698-9. doi: 10.1200/JCO.2007.12.8330. J Clin Oncol. 2007. PMID: 17925571 No abstract available.

5

Erlotinib-induced generalized eczema craquelé and follicular rash sparing the previous radiation field.

Chiu HY, Cheng YP, Jee SH, Tsai TF. Chiu HY, et al. Clin Exp Dermatol. 2012 Dec;37(8):922-4. doi: 10.1111/j.1365-2230.2012.04415.x. Epub 2012 Jun 25. Clin Exp Dermatol. 2012. PMID: 22731795 No abstract available.

6

Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.

Guttman-Yassky E, Mita A, De Jonge M, Matthews L, McCarthy S, Iwata KK, Verweij J, Rowinsky EK, Krueger JG. Guttman-Yassky E, et al. Eur J Cancer. 2010 Jul;46(11):2010-9. doi: 10.1016/j.ejca.2010.04.028. Epub 2010 Jun 2. Eur J Cancer. 2010. PMID: 20621734 Clinical Trial.

7

Painful annular pustular drug eruption induced by erlotinib in a patient with non-small cell lung cancer.

Lin TC, Wu PY. Lin TC, et al. Cutis. 2011 Dec;88(6):281-3. Cutis. 2011. PMID: 22372166 No abstract available.

8

Validation of treatment induced specific adverse effect as a predictor of treatment benefit: a case study of NCIC CTG BR21.

Ding K, Pater J, Whitehead M, Seymour L, Shepherd FA. Ding K, et al. Contemp Clin Trials. 2008 Jul;29(4):527-36. doi: 10.1016/j.cct.2008.01.004. Epub 2008 Jan 19. Contemp Clin Trials. 2008. PMID: 18280222

9

Rosaceiform eruption induced by erlotinib.

Patrizi A, Bianchi F, Neri I. Patrizi A, et al. Dermatol Ther. 2008 Oct;21 Suppl 2:S43-5. doi: 10.1111/j.1529-8019.2008.00233.x. Dermatol Ther. 2008. PMID: 18837734

10

Erlotinib-induced dermatologic side-effects.

Bovenschen HJ, Alkemade JA. Bovenschen HJ, et al. Int J Dermatol. 2009 Mar;48(3):326-8. doi: 10.1111/j.1365-4632.2009.03835.x. Int J Dermatol. 2009. PMID: 19261029 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

74 results

Results by year